Navigation Links
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Date:7/2/2009

ltaq(R) for patients in a therapeutic area that has seen few new treatment options in the last twenty years," said Marc Cluzel, MD, Senior Vice President, Research and Development, sanofi-aventis. "Sanofi-aventis' commitment to research and development in this area is rewarded today, and we hope it will benefit many patients suffering from this disease."

The incidence of atrial fibrillation is growing worldwide in relation to aging populations. It is emerging as a public health concern and affects about 2.5 million people in the United States and 4.5 million people in the European Union. Atrial fibrillation is a potentially life-threatening condition, with significant burden on patients, health care providers and payers.

"It is exciting that Multaq(R) will now be available as a treatment option for patients with paroxysmal or persistent atrial fibrillation or atrial flutter," said Stuart Connolly, M.D., Professor of Medicine & Director, Division of Cardiology, McMaster University, Hamilton, Canada, and co-principal investigator in the ATHENA study. "Based on clinical studies, Multaq(R) reduces the risk of cardiovascular hospitalizations in patients with atrial fibrillation / atrial flutter, this outcome could change the way we approach the management of the disease."

Multaq(R) is to be given twice daily as a 400 mg tablet and should be taken as one tablet with the morning and evening meals. Treatment with Multaq(R) can be initiated in an outpatient setting. Most common adverse reactions are diarrhea, nausea, vomiting, abdominal pain, asthenia (weakness) and cutaneous rash.

A registration dossier of Multaq(R) is also under regulatory review by the European Medicines Agency (EMEA).

About dronedarone (Multaq(R))

Multaq(R), discovered and developed by sanofi-aventis, is one of the major therapeutic i
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
2. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
3. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
4. ClearWay Minnesota(SM) Board Approves Four Regional Grants
5. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
6. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
7. Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
8. FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
9. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
10. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
11. FDA Approves Plan B Pill for 17-Year-Olds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Wash.Researchers at Washington State University Spokane have developed ... about to nod off behind the wheel. , ... wheel movementswhich are more variable in drowsy driversand ... currently available video-based driver drowsiness detection systems. , ... when a car is drifting out of its ...
(Date:4/23/2014)... American Society for Radiation Oncology (ASTRO) has issued ... Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline," ... in the treatment of endometrial cancer. The guideline,s ... issue of Practical Radiation Oncology (PRO), ... full-length guideline is available as an open-access article ...
(Date:4/23/2014)... important enzyme pathway that helps prevent new cells from ... that has been directly linked to cancer and other ... that near the end of cell division, the enzyme ... in DNA are fully repaired before the parent cell ... process helps safeguard against some of the most devastating ...
(Date:4/23/2014)... 23, 2014Men whose testosterone falls below normal levels are ... overweight and have heart disease and type 2 diabetes. ... men for further testing and possible treatment is described ... , a peer-reviewed publication from Mary Ann Liebert, Inc., ... Journal of Men,s Health website at http://www.liebertpub.com/jmh ...
(Date:4/23/2014)... (April 23, 2014) The American Gastroenterological Association ... 2014 AGA Research Scholars. The AGA Research Scholar ... to develop independent and productive research careers in ... Awards fund an additional year allowing for three ... to supporting junior faculty who are paving the ...
Breaking Medicine News(10 mins):Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:AGA announces 2014 Class of AGA Research Scholars 2
... Housing NYC,s Homeless & Mentally IllNEW YORK, April 29 ... shed light on it, philanthropic-minded New Yorkers will raise ... the mentally ill and physically disabled. As federal ... health services in the current economy, supporters will raise ...
... the first about his popular cookie-based diet, Dr. Sanford Siegal combines ... history of weight-loss diets through the Ages , ... ... Diet Book (Hyde Park Publishing Ltd., hardcover, 320 pages, ISBN 978-0-9822728-3-1) ...
... Khanna, founder of the Khanna institute of LASIK is Featured ... LASIK, PRELEX and his expanding practice. , ... Westlake, ... of the Khanna Institute of LASIK, was featured in the highly ...
... leader in on-demand workforce development and productivity, announced today that ... staffing, and management, has switched to the LearnCenter platform to ... partners. , ... (PRWEB) April 29, ...
... cleanup from this year,s record floods continue in the Fargo-Moorhead ... providing the city some badly needed good news. Fargo ... cities for ozone pollution, short-term particle pollution and long-term particle ... live in areas that failed all three tests. The rest ...
... strikes, because of severe pain, often accompanied by nausea and ... up to 72 hours. Since they are forced to stop ... subside, migraine causes a significant loss in productivity at work ... especially the 25% of migraineurs who experience more than three ...
Cached Medicine News:Health News:Weston United Celebrates Mental Health Month on May 19th 2Health News:Dr. Siegal's Cookie Diet Book by Sanford Siegal, D.O., M.D., Available May 22nd 2Health News:Dr. Siegal's Cookie Diet Book by Sanford Siegal, D.O., M.D., Available May 22nd 3Health News:Dr. Siegal's Cookie Diet Book by Sanford Siegal, D.O., M.D., Available May 22nd 4Health News:Dr.Khanna Featured in Highly Respected Trade Journal 2Health News:Dr.Khanna Featured in Highly Respected Trade Journal 3Health News:Emergency Consultants Inc. switches to Learn.com to deliver Continuing Medical Education (CME) courses to physicians 2Health News:Emergency Consultants Inc. switches to Learn.com to deliver Continuing Medical Education (CME) courses to physicians 3Health News:Migraine prevention by targeting glutamate receptors? 2Health News:Migraine prevention by targeting glutamate receptors? 3
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... (Nasdaq: LMNX ) today announced that it expects ... Monday, February 3, 2014. A press release announcing the results ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management will ... financial results for the fourth quarter and twelve months ended ...
(Date:1/14/2014)... Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company of GMH ... Medical Equipment, Inc. ("Progressive") of Clarion, PA ... were not disclosed. Progressive is a full ... of sleep, mobility, and respiratory products to customers in the ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... (NASDAQ: REGN) today announced that it will report ... April 26, 2012, before the U.S. financial markets open.  The ... that day. Live audio of the conference ... webcast may be accessed from the ,Events and Presentations, page ...
... ST. PAUL, Minn., April 11, 2012 Gamma Pharmaceuticals, ... company focused on alternative delivery systems for everyday ... of a Distribution Agreement with Purchase Order for ... order is for approximately $70,000 retail value.  Gamma ...
Cached Medicine Technology:Gamma Pharmaceuticals, Inc. Announces Distribution Agreement for New York Tri-state Area and Purchase Order for Gamma Energy GEL™ 2Gamma Pharmaceuticals, Inc. Announces Distribution Agreement for New York Tri-state Area and Purchase Order for Gamma Energy GEL™ 3
... Vista 1500 integrated system will ... (integrated multisensor technology) and LOCI ... integrate analysis of electrolytes, general ... drugs, immunosuppressive drugs, plasma proteins, ...
... flexibility to floor-mounted X-ray systems. The ... the C-arm around the exam table ... angle for cardiac and general angiography. ... flat panel detector that delivers outstanding ...
... In-office. Information. In real time. The FemExam pH ... elevated vaginal fluid pH (pH >= 4.7) and ... is easy to use and delivers accurate results ... a swab containing unprocessed vaginal fluid across each ...
The Polygraf ID multi-parametric recorder works with POLYGRAM NET analysis software to create a unique interface that combines web-style navigation, graphical presentation and intuitive design to del...
Medicine Products: